Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating adverse events and change in disease activity in adults and adolescents with acute hepatitis C treated with Glecaprevir/Pibrenta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir (glecaprevir)
• Pibrentasvir (pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2025-04-06